Related Experiment Videos
Comments on practice guidelines for the diagnosis and management of aspergillosis made by the IDSA in 2016
E Alarcón-Manoja, C Cardozo-Espinola, P Puerta-Alcalde1
1Pedro Puerta-Alcalde, Department of Infectious Diseases, Hospital Clínic. Villarroel 170, 08036, Barcelona, Spain. pedro.puerta84@gmail.com.
Abstract:
We sought to review the most important updates in the treatment of aspergillosis after the publication of the clinical practice guidelines for the diagnosis and management of invasive aspergillosis (IA) by the Infectious Diseases Society of America. Our aim is to discuss some of the key aspects concerning the following topics: early initiation of antifungal therapy, antifungal agent of choice, follow-up of patients with IA, and breakthrough aspergillosis.
Insights
This review covers key updates in treating invasive aspergillosis (IA), focusing on early antifungal therapy, drug selection, patient monitoring, and breakthrough cases following recent guidelines.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Practice Guidelines
Background:
- Invasive aspergillosis (IA) remains a significant threat, particularly in immunocompromised patients.
- The Infectious Diseases Society of America (IDSA) published clinical practice guidelines for IA diagnosis and management.
- Continuous updates in treatment strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To review significant treatment updates for aspergillosis post-IDSA guidelines publication.
- To discuss critical aspects of IA management, including early antifungal therapy.
- To highlight advancements in antifungal choices, patient follow-up, and breakthrough aspergillosis.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of treatment strategies in the context of established guidelines.
- Synthesis of expert opinion and emerging data on IA management.
Main Results:
- Emphasis on the importance of early initiation of antifungal therapy for improved survival.
- Discussion of preferred antifungal agents and their appropriate use in IA.
- Consideration of strategies for monitoring treatment response and managing breakthrough infections.
Conclusions:
- Timely diagnosis and prompt, appropriate antifungal treatment are essential for invasive aspergillosis.
- Adherence to updated guidelines and consideration of new therapeutic options can optimize patient care.
- Further research is needed to address challenges in managing breakthrough aspergillosis and refractory cases.